The overall performance of the traditional Chinese medicine sector achieved high growth and ushered in greater investment opportunities

 The performance of listed pharmaceutical and biological companies in 2021 is gratifying.
According to statistics, 80% of pharmaceutical companies will achieve a year-on-year increase in operating income in 2021, while 60% of pharmaceutical companies will achieve a year-on-year increase in net profit
.
And many pharmaceutical companies will continue to achieve doubled high growth in the first quarter of 2022 on the basis of doubling or even several times their net profit in 2021
.
Among them, the overall performance of the traditional Chinese medicine sector has also achieved high growth, with 30 traditional Chinese medicine companies having a net profit of more than 100 million yuan
.
The net profit growth rate of Dong'e Ejiao and Tasly is relatively large
.
The data shows that in 2021, Dong'e Ejiao's operating income increased by 12.
89% year-on-year, or about 3.
849 billion yuan; the net profit attributable to shareholders of listed companies increased by 917.
43% year-on-year, or about 440 million yuan; from January to December 2021, Dong'e Ejiao The operating income of Ejiao is as follows: pharmaceutical industry accounts for 93.
77%, donkey breeding and trade account for 4.
64%, and other industries account for 1.
59%
.
In addition, according to the data of the 2022 first quarter report released by Dong'e Ejiao recently, the company's revenue in the first quarter of 2022 increased by 21.
4% year-on-year, or about 890 million yuan; the net profit attributable to shareholders of the listed company increased by 86.
01% year-on-year, about 115 million yuan Yuan
.
In 2021, Tasly's net profit attributable to shareholders of listed companies increased by 109.
51% year-on-year, or about 2.
359 billion yuan
.
The annual report shows that Tasly's pharmaceutical industry revenue in 2021 will increase by 4.
25% year-on-year to 6.
654 billion yuan
.
Among them, the revenue of the traditional Chinese medicine sector was 5.
080 billion yuan, with a growth rate of 13.
74%
.
The company is increasing its marketing network to serve primary medical institutions, so that basic drug products such as Compound Danshen Dripping Pills, Qishen Yiqi Dripping Pills, and Yangxuenao Granules (Pills) have achieved rapid growth
.
In 2021, the company's compound Shendan dripping pill shipments increased by 13.
12% year-on-year, reaching 122 million boxes, achieving rapid growth
.
The shipment volume of Qishen Yiqi Dropping Pills increased by 21.
39% year-on-year to 17.
04 million boxes
.
The shipment of Yangxuexuenao Granules increased by 20.
34% year-on-year to 25.
91 million boxes; the shipment of Yangxuexuenao Pills increased by 28.
22% year-on-year to 7.
73 million boxes
.
The company has accelerated the secondary development of large varieties.
The research and development process of Qishen Yiqi Dropping Pills for heart failure indications and Yangxuenao Pills for Alzheimer's disease (AD) indications are progressing steadily
.
In addition, Baiyunshan's operating income in 2021 will increase by 11.
90% year-on-year to 69.
014 billion yuan; total profit will increase by 26.
32% year-on-year to 4.
723 billion yuan; net profit attributable to shareholders of the company will increase by 27.
60% year-on-year to 3.
720 billion yuan; operating activities The net cash flow generated increased by 869.
52% year-on-year to 5.
673 billion yuan
.
It is understood that in recent years, traditional Chinese medicine has been continuously beneficial at the policy level.
The National Medical Insurance Administration and the State Administration of Traditional Chinese Medicine jointly issued the "Guiding Opinions on Medical Insurance Supporting the Inheritance, Innovation and Development of Traditional Chinese Medicine", etc.
Continuously promote the development of traditional Chinese medicine industry
.
Under the impetus of favorable policies, the market of traditional Chinese medicine industry also showed a trend of steady growth
.
Among them, the scale of China's traditional Chinese medicine pharmaceutical market in 2021 may reach 75.
3 billion yuan
.
Under the promotion of various favorable policies, many traditional Chinese medicine companies such as Kangenbei, Tasly, Dong'e Ejiao, and Zuoli Pharmaceutical have doubled their performance in 2021.
In addition, Xiangcai Securities said that the traditional Chinese medicine industry has welcomed the policy support in recent years.
for greater investment opportunities
.
In terms of demand, factors such as the rigid demand characteristics of the pharmaceutical industry and the upgrading of pharmaceutical consumption jointly support the steady growth of demand in the Chinese medicine industry; in terms of policies, a series of favorable policies such as promoting the innovation of traditional Chinese medicine, the development of formula granules, and the anti-epidemic of traditional Chinese medicine have brought new growth to the industry.
demand
.
At the same time, the traditional Chinese medicine industry currently has a relatively obvious valuation advantage, and the industry performance shows a marginal improvement trend
.
Can focus on branded traditional Chinese medicine, innovative traditional Chinese medicine and other fields
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.